MX2019010248A - Composiciones y metodos para producir cetosis elevada y sostenida. - Google Patents

Composiciones y metodos para producir cetosis elevada y sostenida.

Info

Publication number
MX2019010248A
MX2019010248A MX2019010248A MX2019010248A MX2019010248A MX 2019010248 A MX2019010248 A MX 2019010248A MX 2019010248 A MX2019010248 A MX 2019010248A MX 2019010248 A MX2019010248 A MX 2019010248A MX 2019010248 A MX2019010248 A MX 2019010248A
Authority
MX
Mexico
Prior art keywords
ketosis
blood
medium chain
dietary restriction
initiating
Prior art date
Application number
MX2019010248A
Other languages
English (en)
Inventor
Paul D'agostino Dominic
arnold Patrick
Kesl Shannon
Original Assignee
Univ South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51581503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019010248(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ South Florida filed Critical Univ South Florida
Publication of MX2019010248A publication Critical patent/MX2019010248A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Las sales minerales de beta-hidroxibutirato en combinación con ácidos grasos de cadena media o un éster de los mismos tales como triglicéridos de cadena media, se utilizaron para inducir cetosis, alcanzando niveles de cetona en sangre de (2-7 mmol/L), con o sin restricción alimenticia. La combinación da por resultado en mejoras sustanciales en los biomarcadores metabólicos con relación a la resistencia a insulina, diabetes, pérdida de peso y desempeño físico en un período de tiempo corto. Además, el uso de estos suplementos para alcanzar la cetosis proporciona una elevación significativa de cetonas en sangre y la reducción de niveles de glucosa en sangre. El uso de estas sustancias no afecta adversamente los perfiles lipídicos. Al iniciar una cetosis rápida y al acelerar la velocidad de ceto-adaptación, esta invención es útil para evitar los síntomas de retiro de glucosa experimentados comúnmente por individuos que inician una dieta cetogénica, y reduce al mínimo la pérdida de masa corporal magra durante una restricción alimenticia.
MX2019010248A 2013-03-19 2015-09-17 Composiciones y metodos para producir cetosis elevada y sostenida. MX2019010248A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361803203P 2013-03-19 2013-03-19
US201461926664P 2014-01-13 2014-01-13

Publications (1)

Publication Number Publication Date
MX2019010248A true MX2019010248A (es) 2019-10-09

Family

ID=51581503

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015013312A MX371259B (es) 2013-03-19 2014-03-19 Composiciones y métodos para producir cetosis elevada y sostenida.
MX2019010248A MX2019010248A (es) 2013-03-19 2015-09-17 Composiciones y metodos para producir cetosis elevada y sostenida.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015013312A MX371259B (es) 2013-03-19 2014-03-19 Composiciones y métodos para producir cetosis elevada y sostenida.

Country Status (21)

Country Link
US (4) US9138420B2 (es)
EP (1) EP2976073B1 (es)
JP (2) JP6491189B2 (es)
KR (2) KR102499654B1 (es)
CN (1) CN105050594B (es)
AU (2) AU2014236004B2 (es)
BR (1) BR112015024186B1 (es)
CA (1) CA2902603C (es)
CL (2) CL2015002802A1 (es)
CR (1) CR20150579A (es)
HK (1) HK1216847A1 (es)
IL (2) IL241316B (es)
MX (2) MX371259B (es)
MY (1) MY180761A (es)
NZ (1) NZ711433A (es)
PE (1) PE20151949A1 (es)
PH (1) PH12015501966B1 (es)
RU (2) RU2018120938A (es)
SG (2) SG11201506780RA (es)
WO (1) WO2014153416A1 (es)
ZA (1) ZA201506387B (es)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2670413T3 (es) 2003-06-03 2018-05-30 The United States Government As Represented By The Department Of Health And Human Services Suplementos nutricionales y composiciones terapéuticas que comprenden derivados de (R)-3-hidroxibutirato
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
ES2752030T3 (es) 2012-11-05 2020-04-02 Us Health Cuerpos cetónicos para proteger los tejidos del daño por radiación ionizante
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
CN105377252A (zh) 2013-03-14 2016-03-02 佛罗里达大学研究基金会 利用天然化合物和/或饮食调控癌症
SG11201507685UA (en) 2013-03-14 2015-10-29 Isis Innovation Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate
GB201314127D0 (en) * 2013-08-07 2013-09-18 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown
EP3125904A4 (en) 2014-04-02 2017-08-30 University of Southern California Autoimmunity and multiple sclerosis treatment
US11020372B2 (en) 2015-03-24 2021-06-01 University Of Florida Research Foundation, Incorporated Dietary and natural product management of negative side effects of cancer treatment
CA2988589A1 (en) * 2015-06-26 2016-12-29 University Of Florida Research Foundation, Incorporated Method of treating inflammation using natural compounds and/or diet
US10987340B2 (en) 2015-07-24 2021-04-27 Jesse Alexander Galinski Composition and method for rapidly inducing an endogenous ketosis
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US10292952B2 (en) * 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US10245243B1 (en) * 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10245242B1 (en) * 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US20170266147A1 (en) * 2016-03-18 2017-09-21 Csilla Ari D'Agostino Methods of increasing latency of anesthetic induction using ketone supplementation
WO2017165445A1 (en) * 2016-03-21 2017-09-28 Csilla Ari D'agostino Administration of exogenous ketone to lower blood glucose
EP3463320A4 (en) * 2016-03-21 2019-12-25 University of South Florida METHODS FOR IMPROVING MOTOR FUNCTION BY KETONE SUPPLEMENTATION
US10376482B2 (en) 2016-04-03 2019-08-13 Franco Cavaleri Butyrate and beta-hydroxybutyrate compositions
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
CA3021784A1 (en) * 2016-04-19 2017-10-26 Keto Patent Group, Inc. Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
WO2017184789A1 (en) * 2016-04-19 2017-10-26 Keto Patent Group, Inc. Administration of berberine metabolites
WO2017208217A2 (en) 2016-06-01 2017-12-07 Aspi Ip Holder Llc C5 ketone compositions, and related methods, for therapeutic and performance supplementation
RU2761829C2 (ru) 2016-06-07 2021-12-13 Зе Дж. Дэвид Глэдстоун Инститьютс Образуемые среднецепочечными жирными кислотами сложные эфиры бета-гидроксибутирата и бутандиола и композиции и способы на их основе
US10588877B2 (en) 2016-07-21 2020-03-17 Savind, Inc. Compositions comprising β-hydroxybutyric acid and salt, and methods of using the same
JP6935994B2 (ja) 2016-08-19 2021-09-15 株式会社明治 ケトン体生成促進用組成物
US20180057846A1 (en) * 2016-08-30 2018-03-01 KetoneAid Inc. Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy
WO2018052758A1 (en) * 2016-09-13 2018-03-22 Abbott Laboratories Ketogenic nutritional compositions
EP3528802A4 (en) * 2016-10-24 2020-05-13 University Of South Florida DELAY IN LATENCY LEADING TO A CRISIS BY COMBINATIONS OF KETONIC SUPPLEMENTS
US20180177753A1 (en) * 2016-12-23 2018-06-28 Neuroenergy Ventures, Inc. Glyceryl 3-hydroxybutyrates for migraine symptom management
US9925164B1 (en) 2017-01-12 2018-03-27 Neuroenergy Ventures, Inc. Glyceryl 3-hydroxybutyrates for traumatic brain injury
EP3592213B1 (en) * 2017-03-08 2023-03-22 Abbott Diabetes Care Inc. System for wellness and nutrition monitoring and management using analyte data
US11571376B2 (en) * 2017-03-28 2023-02-07 Arxada Ag Aqueous antimicrobial composition
JP6968624B2 (ja) * 2017-04-06 2021-11-17 株式会社明治 ケトン食摂取量の管理方法
WO2018186481A1 (ja) * 2017-04-06 2018-10-11 株式会社明治 ケトン食の有効状態のモニタリング装置
WO2018187852A1 (en) * 2017-04-12 2018-10-18 Cavaleri Franco Butyrate and beta-hydroxybutyrate compositions and methods of use thereof
CN107083406B (zh) * 2017-05-27 2021-02-02 浙江华睿生物技术有限公司 (r)-3-羟基丁酸的生产方法
GB201710229D0 (en) 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use
EP3654963A4 (en) 2017-07-21 2021-04-14 Buck Institute for Research on Aging BETA-HYDROXYBUTYRATE AND BUTANEDIOL S ENANTIOMERS AND THEIR METHODS OF USE
CN109394745A (zh) * 2017-08-17 2019-03-01 博瑞生物医药（苏州）股份有限公司 一种包含左旋肉碱和β-羟基丁酸化合物的组合物
US11760963B2 (en) 2017-08-23 2023-09-19 KetoneAid Inc. Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol
GB201715654D0 (en) * 2017-09-27 2017-11-08 Tdeltas Ltd Method of treatment
US20190119705A1 (en) * 2017-10-20 2019-04-25 KetoneAid Inc. Substantially non-racemic ketone ester of beta hydroxybutyrate and production process thereof
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11596616B2 (en) 2017-12-12 2023-03-07 University Of South Florida Compositions and methods for weight loss maintenance
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
JP2021509686A (ja) * 2018-01-05 2021-04-01 テキサス・テック・ユニバーシティー・オフィス・オブ・リサーチ・コマーシャライゼーション 間欠性絶食に関連するβ−ヒドロキシ−β−メチルブチレート（ＨＭＢ）の組成物およびその使用法
KR20200116096A (ko) * 2018-02-01 2020-10-08 웰스태트 테러퓨틱스 코포레이션 우리딘의 전신 전달을 위한 조성물 및 장치
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US20200061023A1 (en) * 2018-08-27 2020-02-27 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US10512615B1 (en) 2018-08-27 2019-12-24 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US10980772B2 (en) * 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US11484542B2 (en) 2018-05-30 2022-11-01 Adam Slank Specialized tongue spray containing gymnemic acid and exogenous ketones
WO2019234628A1 (en) * 2018-06-07 2019-12-12 Société des Produits Nestlé S.A. Methods and compositions for increasing ketone bodies in animals
CA3022995C (en) * 2018-06-12 2019-10-15 Ketofibe (9211-3133 Quebec Inc.) Novel ketogenic compounds, compositions, methods and use thereof
CA3099624A1 (en) * 2018-06-21 2019-12-26 Societe Des Produits Nestle S.A. Compositions and methods using a nicotinamide adenine dinucleotide (nad+) precursor and at least one ketone or ketone precursor
WO2020041871A1 (en) * 2018-08-27 2020-03-05 Exerkine Corporation Method for treating lysosomal storage disease
US20200068939A1 (en) * 2018-09-04 2020-03-05 Jho Intellectual Property Holdings Llc Nutritional compositions to increase and sustain blood ketone levels
JP2022502489A (ja) 2018-09-25 2022-01-11 ポンス デ レオン ヘルス デジグネイテッド アクティビティ カンパニー αケトグルタル酸カルシウムを製造するためのプロセス
US20210338613A1 (en) * 2018-10-05 2021-11-04 Dyve Biosciences, Inc. Formulations and methods for transdermal administration of ketones
EP3873442A4 (en) * 2018-10-29 2022-08-10 Keto Patent Group, Inc. MANUAL ADMINISTRATION OF BUTYRATE, BETA-HYDROXYBUTYRATE, CANNABIDIOL AND RELATED COMPOUNDS
CN109480284A (zh) * 2018-12-05 2019-03-19 上海欣海生物科技有限公司 一种生酮食品及其制备方法
EP3897178A1 (en) * 2018-12-18 2021-10-27 Société des Produits Nestlé S.A. Mixed triglyceriges
CN109734575A (zh) * 2019-01-04 2019-05-10 上海欣海国际贸易有限公司 一种制备3-羟基丁酸氨基酸盐复合物的方法
EP3923918A4 (en) * 2019-02-11 2022-10-05 Access Global Sciences, LLC MIXED BETA HYDROXYBUTYRATE HCL ACID COMPOSITIONS AND METHODS OF USE
WO2020167690A1 (en) * 2019-02-11 2020-08-20 Access Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
AU2020221916A1 (en) * 2019-02-11 2021-09-02 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
JP7281927B2 (ja) * 2019-03-14 2023-05-26 大阪瓦斯株式会社 心拍数低減剤
AU2020235643A1 (en) * 2019-03-14 2021-09-30 Augusta University Research Institute, Inc. Methods and compositions for supporting renal health
EP3941455A1 (en) * 2019-03-22 2022-01-26 Société des Produits Nestlé S.A. Methods using administration of medium chain triglycerides (mct) prior to a meal to increase ketone production from the mcts
JP7459142B2 (ja) * 2019-06-12 2024-04-01 ケトリピックス セラポーティクス ゲーエムベーハー アシルキャップされた３－ヒドロキシカルボン酸のポリオール系エステルの製造方法
WO2020249197A1 (de) * 2019-06-12 2020-12-17 Ioi Oleo Gmbh Verfahren zur herstellung von acylverkappten 3-hydroxycarbonsäuren sowie deren salzen und estern
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11915605B2 (en) 2019-10-17 2024-02-27 Nicolas Tzenios Ketogenic diet recommendation to a user based on a blood low-density lipoprotein (LDL) level and a blood C-reactive protein level and/or a blood erythrocyte sedimentation rate (ESR) thereof
US20230172891A1 (en) * 2020-01-23 2023-06-08 University Of South Florida Prevention and treatment of effects of aging and age-associated disorders with ketone supplementation
EP4114203A1 (en) 2020-03-05 2023-01-11 VitaNav, Inc. COMPOSITION OF (D)-ß-HYDROXYBUTYRIC ACID, (D)-ß-HYDROXYVALERIC ACID, AND (D)-1,3 BUTANEDIOL AS A NUTRITIONAL SUPPLEMENT AND THERAPEUTIC AGENT
CA3182791A1 (en) * 2020-06-14 2021-12-23 Fabrizio SCHIRANO An intermittent fasting bar/drink that maintains and extends the fasting state
CA3188646A1 (en) * 2020-07-02 2022-01-06 Ponce De Leon Health Designated Activity Company Compositions and methods for treating crp-mediated diseases
US20220062216A1 (en) * 2020-08-26 2022-03-03 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
CN112137115A (zh) * 2020-09-25 2020-12-29 深圳市捷利康生物科技有限公司 具有增强免疫力功效的生酮营养粉及其制备方法
WO2022140279A1 (en) * 2020-12-22 2022-06-30 Buck Institute For Research On Aging Synergistic modulators of alpha-dicarbonyl detoxification and their use for inducing weight loss and the treatment of diabetic pathologies
EP4329519A1 (en) * 2021-04-26 2024-03-06 University of South Florida Methods for treating symptoms of kabuki syndrome
RU2769242C1 (ru) * 2021-06-16 2022-03-29 Александр Владимирович Чемоданов Кетогенная композиция
WO2023278240A1 (en) 2021-06-28 2023-01-05 Phb Industrial S.A. Methods to produce therapeutic formulations comprising hydroxybutirate and hydroxyvalerate, therapeutic formulations and uses thereof
WO2023112817A1 (ja) * 2021-12-14 2023-06-22 サントリーホールディングス株式会社 ３ヒドロキシ酪酸及び低級脂肪族アルコールを含有する飲料及び呈味改善方法
WO2023112818A1 (ja) * 2021-12-14 2023-06-22 サントリーホールディングス株式会社 炭酸飲料及び炭酸飲料の炭酸感を増強する方法
CN114306308A (zh) * 2021-12-24 2022-04-12 苏州麦轮生物科技有限公司 一种含有酮酯的营养补充剂及其应用
WO2023139357A1 (en) * 2022-01-18 2023-07-27 Today Inc. Molecules, nutritional formulations, and methods of providing nutritional support
JP7223193B1 (ja) 2022-05-26 2023-02-15 大阪瓦斯株式会社 内臓脂肪低減剤およびその用途
CN115192603B (zh) * 2022-07-06 2023-04-21 西北农林科技大学 锂盐在制备防治奶牛酮病制剂中的应用
CN115251375A (zh) * 2022-07-11 2022-11-01 珠海麦得发生物科技股份有限公司 一种(r)-3-羟基丁酸生酮产品及其制备方法
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8803141L (sv) * 1988-09-07 1990-03-08 Kabivitrum Ab Naeringsmedel foer maenniskor och djur
US5654266A (en) * 1992-02-10 1997-08-05 Chen; Chung-Ho Composition for tissues to sustain viability and biological functions in surgery and storage
ES2530753T3 (es) * 1997-03-17 2015-03-05 Btg Int Ltd Composiciones terapéuticas que comprenden cuerpos cetónicos y precursores de los mismos
US6316038B1 (en) 1997-03-17 2001-11-13 Btg International Limited Therapeutic compositions
US20090253781A1 (en) 2002-05-24 2009-10-08 Btg International Limited Therapeutic compositions
US6323237B1 (en) 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
JPH1160434A (ja) 1997-08-12 1999-03-02 Kanebo Ltd 皮膚老化防止化粧料
EP1098655B1 (en) * 1998-07-22 2004-11-24 Metabolix, Inc. Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers
WO2000015216A1 (en) 1998-09-15 2000-03-23 Btg International Limited Therapeutic compositions (ii)
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
ES2323940T3 (es) 2000-05-01 2009-07-28 Accera, Inc. Uso de trigliceridos de cadena media para el tratamiento y prevencion de la enfermedad de alzheimer.
US6613356B1 (en) 2000-10-10 2003-09-02 Victor Vlahakos Weight loss medication and method
US20050129783A1 (en) * 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
US8158184B2 (en) * 2004-03-08 2012-04-17 Bunge Oils, Inc. Structured lipid containing compositions and methods with health and nutrition promoting characteristics
GB0410266D0 (en) * 2004-05-07 2004-06-09 Ketocytonyx Inc Treatment of apoptosis
GB0420856D0 (en) 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
US20070135376A1 (en) * 2005-06-20 2007-06-14 Accera, Inc. Method to reduce oxidative damage and improve mitochondrial efficiency
EP2001293B9 (en) * 2006-04-03 2019-04-17 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
US7807718B2 (en) 2006-06-30 2010-10-05 Sami A. Hashim Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
MX2009011002A (es) * 2007-04-12 2010-03-15 Univ Minnesota Composiciones de proteccion de isquemia/reperfusion y metodos de uso.
AU2009204370B2 (en) * 2008-01-04 2014-12-04 Gvmt Of The Usa, As Represented By The Secretary, Department Of Health & Human Services Ketone bodies and ketone body esters as blood lipid lowering agents
GB201002983D0 (en) * 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
GB201206192D0 (en) 2012-04-05 2012-05-23 Tdeltas Ltd Ketone bodies and ketone body esters and for maintaining or improving muscle power output

Also Published As

Publication number Publication date
EP2976073A4 (en) 2017-02-22
KR20220011785A (ko) 2022-01-28
US9138420B2 (en) 2015-09-22
IL259502A (en) 2018-07-31
US20170266148A1 (en) 2017-09-21
MX2015013312A (es) 2016-06-07
CL2015002802A1 (es) 2016-05-06
PH12015501966A1 (en) 2016-01-11
NZ711433A (en) 2017-03-31
AU2019200511A1 (en) 2019-02-14
CA2902603C (en) 2021-03-02
PH12015501966B1 (en) 2016-01-11
IL259502B (en) 2019-09-26
US9675577B2 (en) 2017-06-13
BR112015024186A2 (pt) 2017-07-18
PE20151949A1 (es) 2016-01-05
US20200268701A1 (en) 2020-08-27
JP2019031578A (ja) 2019-02-28
AU2014236004A1 (en) 2015-09-10
RU2015136190A (ru) 2017-03-10
CL2018000983A1 (es) 2018-10-12
AU2014236004B2 (en) 2018-10-25
IL241316B (en) 2018-08-30
MY180761A (en) 2020-12-08
SG10201808690PA (en) 2018-11-29
JP6491189B2 (ja) 2019-03-27
US20160067207A1 (en) 2016-03-10
CN105050594A (zh) 2015-11-11
WO2014153416A1 (en) 2014-09-25
KR20150130312A (ko) 2015-11-23
CN105050594B (zh) 2019-11-12
MX371259B (es) 2020-01-23
ZA201506387B (en) 2017-08-30
EP2976073A1 (en) 2016-01-27
US20140350105A1 (en) 2014-11-27
KR102499654B1 (ko) 2023-02-13
HK1216847A1 (zh) 2016-12-09
IL241316A0 (en) 2015-11-30
US10646462B2 (en) 2020-05-12
RU2018120938A3 (es) 2019-04-04
CR20150579A (es) 2016-01-04
JP2016514725A (ja) 2016-05-23
BR112015024186B1 (pt) 2023-05-09
RU2659386C2 (ru) 2018-06-29
SG11201506780RA (en) 2015-10-29
EP2976073B1 (en) 2019-08-28
CA2902603A1 (en) 2014-09-25
RU2018120938A (ru) 2018-11-06

Similar Documents

Publication Publication Date Title
MX2019010248A (es) Composiciones y metodos para producir cetosis elevada y sostenida.
BR112014019927B8 (pt) Fórmula nutricional, seu método de preparação, seu uso, dispositivos e composição
TW201613559A (en) Emulsion composition
JP2012120528A5 (es)
PH12015501688B1 (en) Nutritional compositions containing magnesium threonate and uses thereof
BR112015005933A2 (pt) composição nutricional para mulher grávida com um perfil benéfico de glicose e insulina
GR1008345B (el) Μεθοδος παρασκευης προϊοντων με βαση τα ολοκληρα τεμαχια κρεατος και μορφοποιημενων προϊοντων, που περιεχουν ελαιο
BR112012001373A2 (pt) Produto comestível, métodos para produzir um produto comestível melhorado que inclui um complexo de cafeína bruta, para estimular a captação de glicose pelas células, para reduzir os níveis de glicose sanguínea em um organismo tendo níveis de glicose sanguíneo elevados, para suplementar uma dieta pelo aumento de ingestão dietética total de antioxidantes em um organismo, e para reduzir a atividade inflamatória em um organismo tendo níveis inflamatórios elevados, e, composição de matéria
IN2014MU04013A (es)
BRPI0918723A8 (pt) Composição de gordura ou óleo
WO2014083546A3 (en) Method of determining effect of anti-obesity molecule
Pan et al. Sleep Enhancement of Visual Discrimination Performance is Modulated by Training Paradigm
UA41334U (ru) Способ оценки эффективности применения кратала
UA71032U (ru) Способ оценки жирнокислотного спектра липидов висцеральных адипоцитов у пациентов с метаболическим синдромом
Chudak et al. HEMATOLOGICAL INDICES OF QUAILS UNDER THE EFFECT OF PROBIOTIC" ENTRO-ACTIVE"
UA92854U (uk) Спосіб визначення порушень ліпідного метаболізму в тромбоцитах у хворих з постійною формою фібриляції передсердь
UA87252U (ru) Способ оценки липидных нарушений у больных с постоянной формой фибрилляции предсердий
Chudak et al. HEMATOLOGICAL INDICES OF QUAILS UNDER THE EFFECT OF PROBIOTIC" ENTRO-ACTIVE"
大竹 et al. Dietary nitrite supplementation improves insulin resistance in type 2 diabetic KKAy mice
UA98436U (ru) Способ оценки нарушений липидного метаболизма в элементах крови у больных с ишемической болезнью сердца
UA92943U (uk) Спосіб оцінки ефективності корекції ліпідних порушень в еритроцитах щурів за коразолової моделі судомного синдрому
Wang et al. Change of plasma very long chain fatty acids in obese children
Yancar Demir Hyperprolactinaemia in an elderly patient: case report
UA62797U (ru) Способ оценки нарушений липидного метаболизма после оперативного вмешательства на костях челюстно-лицевой области
UA61835U (ru) Способ определения степени нарушений липидного метаболизма у больных с ишемической болезнью сердца